The WEE1 kinase is a central regulator of G2/M and S phase cell cycle checkpoints which is potently activated in response to DNA damage. To date, a number of biomarker candidates have been proposed for WEE1 monotherapy sensitivity, including TP53 alterations, however, there is currently limited clinical evidence that biomarker-positive patient populations are significantly enriched in response to WEE1 inhibitors. Debio 0123 is a WEE1 inhibitor that has previously shown significant preclinical efficacy as a single agent and is currently being investigated in phase 1 clinical studies either as a monotherapy or in combination with different therapies. Herein we present a first-generation digital biomarker utilizing the ResponderID™ framework and the Genialis™ Supermodel to configure a model capable of predicting responders from non-responders to the Debio 0123 WEE1 inhibitor.